

LEVERAGING SPACE TO HELP PATIENTS REGAIN SIGHT



Nicole L. Wagner, PhD CHIEF EXECUTIVE OFFICER

RETINAL DEGENERATIVE DISEASES





RETINITIS PIGMENTOSA (RP)

1.5M Global Population (>\$4B US/EU Market) AGE-RELATED MACULAR DEGENERATION (AMD) 50M Global Population (>\$300B US/EU Market)

COMPETITION



DEVICE-BASED

GENE THERAPEUTICS



- Bulky
- Hardware driven
- Low-resolution
- Many discontinued

- Unproven
- Invasive
- Limited patient population
- Potential off target activity

LAMBDAVISION'S SOLUTION



SPACE IMPROVES QUALITY AND SCALABILITY

Protein-based Artificial Retina

200 ultrathin layers











ROADMAP



LEADERSHIP and CORE TEAM







Nicole Wagner, PhD, CEO PhD Biochemistry – UConn

Jordan Greco, PhD, CSO PhD Physical Chemistry – UConn

Expertise Regulatory Manufacturing Preclinical **Experience** Bioelectronics Optogenetics Machine Learning

7

RAISING \$7M SEED ROUND

CAPITAL

Type of Financing: SAFE

> Target Raise: \$7M

Committed Funds: >\$3M

USE OF FUNDS





Manufacturing Process Development/ cGMP Scale-up



IND-enabling Preclinical Studies





Through development of the first protein-based artificial retina LambdaVision is pioneering solutions in space that will pave the way for the future of many industries

Dr. Nicole L. Wagner, PhD, CEO nicole.wagner@lambda**vision**.com 774-280-0525



